Physician profile
Eileen Bishop
NPI 1356349708
$1,041.57
in general payments reported to CMS, 2019-2025
18 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.51 · 2020: $24.28 · 2022: $103 · 2023: $186 · 2024: $338 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Artivion, INC. | $117.93 | 2025 | On-X Aortic Heart Valve With Conform-X Sewing Ring and Extended Holder, Cryovalve Sg Pulmonary Human Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $97.47 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $94.53 | 2025 | |
| Janssen Pharmaceuticals, INC | $94.32 | 2022-2024 | Xarelto |
| Boston Scientific Corporation | $90.34 | 2024-2025 | Watchman Flx |
| Atricure, INC. | $80.33 | 2019-2024 | |
| Pfizer INC. | $69.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $66.33 | 2019-2024 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $51.75 | 2023 | Arcalyst |
| Abbott Laboratories | $45.47 | 2023-2024 | Cardiomems, Navitor |
| Kiniksa Pharmaceuticals International, Plc | $41.21 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $36.31 | 2022-2025 | Nexletol |
| Cvrx, INC. | $33.82 | 2024 | Barostim Neo System |
| Philips North America LLC | $27.46 | 2024 | (Cm9) Amb Mon & Diag Und |
| Inspire Medical Systems, INC. | $26.92 | 2024 | Inspire |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $25.47 | 2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $24.61 | 2024 | |
| Novo Nordisk INC | $18.30 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.